Humalog Tempo Pen (Insulin Lispro)

Humalog Tempo Pen is indicated for the management of blood glucose in adults and children with diabetes, providing rapid‑acting insulin coverage for various therapeutic scenarios.

• Rapid‑acting insulin therapy for Type 1 diabetes mellitus.
• Mealtime (prandial) insulin control in Type 2 diabetes mellitus.
• Supplemental insulin when basal regimens are insufficient.
• Use in insulin‑pump transition periods or during sick‑day management.
• Adjustments for exercise‑induced glucose variability.

• Insulin lispro is a rapid‑acting insulin analog that differs from human insulin by two amino‑acid substitutions, reducing its tendency to form hexamers. After subcutaneous injection, the monomeric form is rapidly absorbed into the bloodstream, where it binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers intracellular signaling that enhances glucose transporter (GLUT4) translocation, increases glucose uptake, and suppresses hepatic glucose production, thereby lowering plasma glucose levels.

Like all insulin products, Humalog Tempo Pen may be associated with adverse reactions, which are generally categorized by frequency and severity.

Common

• Mild to moderate hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Redness, swelling, or itching at the injection site.
• Small lumps of fatty tissue (lipohypertrophy) under the skin with repeated injections.
• Transient weight gain due to increased glucose utilization.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent low blood potassium (hypokalemia) in rare cases.

Before initiating therapy with Humalog Tempo Pen, several precautionary considerations should be reviewed to ensure safe and effective use.

• Verify diagnosis of diabetes and need for rapid‑acting insulin.
• Assess for hypoglycemia unawareness or frequent episodes.
• Consider renal or hepatic impairment that may affect insulin clearance.
• Review pregnancy or breastfeeding status, as insulin requirements may change.
• Educate on proper injection technique and rotation of sites to prevent lipohypertrophy.
• Monitor blood glucose closely during dose adjustments, illness, or changes in physical activity.
• Store the pen according to manufacturer instructions, avoiding extreme temperatures.

Humalog Tempo Pen can interact with other medicines or substances that influence blood glucose levels or insulin action, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent use of other rapid‑acting insulin products without dose adjustment.
• Combining with high‑dose sulfonylureas or meglitinides, which may precipitate severe hypoglycemia.
• Administration with beta‑blockers that can mask hypoglycemia symptoms.

Use with caution

• Corticosteroids, which can raise blood glucose and require insulin dose increase.
• Thiazide diuretics, which may affect potassium levels and insulin sensitivity.
• Alcohol, especially in excess, as it can cause delayed hypoglycemia.